A new double-arc intrastromal corneal ring segment may help to improve visual outcomes and rehabilitate the physiologic optical surface by remodelling the cornea
Steroids are an important second-line treatment for the treatment of diabetic macular oedema. While side effects remain a concern, modern formulations of intravitreal steroid allow the treatment to be tailored to the individual patient.
Current IOL designs offer a variety of optical options for the correction of presbyopia. Regardless of the principal of correction, compromise is required. However, a new class of IOLs, currently referred to as extended-depth-of-focus IOLs (EDOF-IOLs), seems to be generating very satisfied patients.
In a Phase IIa study of patients with neovascular age-related macular degeneration, a single subretinal injection of rAAV.sFlt-1 gene therapy (AVA-101) demonstrated acceptable safety, but not a complete or durable response. Additional preclinical research is underway.
While traditional transscleral cyclophotocoagulation is effective at lowering IOP in patients with glaucoma, it has a high rate of side effects. The new MicroPulse system is effective and affordable with an excellent safety profile.